SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study

Published on 10 Jan 2025 on Zacks · via Yahoo Finance

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage...

Read the rest of the article

Start tracking your investments with Statfolio

AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in...

Zacks · via Yahoo Finance 20 Feb 2025

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzog...

Zacks · via Yahoo Finance 20 Feb 2025

Zealand Pharma stock falls loss widens, revenue declines

Investing.com 20 Feb 2025

(Bloomberg) -- European stocks suffered their biggest decline in two months, hit by the possibili...

Bloomberg · via Yahoo Finance 19 Feb 2025

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere,...

BioPharma Dive · via Yahoo News 19 Feb 2025

The sBLA is based on data from a pivotal study that demonstrated that Dupixent led to significant...

Zacks · via Yahoo Finance 18 Feb 2025

PFE, NVS and ABBV have a Zacks Rank #3 (Hold) each, while Sanofi and RHHBY have a Zacks Rank #4...

Zacks · via Yahoo Finance 14 Feb 2025

France stocks higher at close of trade; CAC 40 up 0.18%

Investing.com 14 Feb 2025

CRSP beat on earnings in three of the trailing four quarters and missed the mark in the other,...

Zacks · via Yahoo Finance 3 Feb 2025

Sanofi is not the only big pharma company targeting a share buyback campaign. On the back of boom...

Pharmaceutical Technology · via Yahoo Finance 3 Feb 2025